Literature DB >> 33664943

Trans-cutaneous electrical nerve stimulation to treat dry mouth (xerostomia) following radiotherapy for head and neck cancer. A systematic review.

Fatemeh Salimi1, Francisco Saavedra2,3, Brain Andrews3, James FitzGerald3, Stuart C Winter3.   

Abstract

BACKGROUND: A dry mouth or xerostomia is one of the most common long-term complications following radiotherapy for head and neck cancer and has a negative impact on quality of life in cancer survivors. Transcutaneous electrical nerve stimulation (TENS) is a novel approach to improving saliva flow in these patients.
OBJECTIVE: To perform a systematic review of studies evaluating TENS in the treatment of radiotherapy induced xerostomia in head and neck cancer patients. DATA COLLECTION AND ANALYSIS: A comprehensive electronic search was performed in PubMed/MEDLINE, the Cochrane Library, and Google Scholar databases for appropriate published studies. The last search was conducted in January 2020. Two review authors assessed all studies identified by the search strategy and carried out data extraction.
RESULTS: Five studies were included in the systematic review which analysed a total of 280 patients with head and neck cancer. Methodological quality and outcomes were evaluated in every study included. The outcome measure was either subjectively assessed or objectively measured. Three studies used conventional TENS therapy to stimulate parotid glands which produced a significant increase in saliva production following therapy. Two studies used acupunctured TENS type to electrically stimulate acupuncture points scattered in the body and they reported improvement in saliva production at the same level as medical treatment. No reported adverse effect of TENS was identified.
CONCLUSIONS: This systematic review confirms the safety and feasibility of TENS in the treatment of xerostomia. It is established that commencing daily TENS therapy simultaneously with radiotherapy has the most efficacy. Given the nonspecific parameters used in the included studies, further evidence is needed in order to establish optimal settings and parameters of TENS for treatment of xerostomia.
© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.

Entities:  

Keywords:  Dry mouth in patients with head and neck cancer; Head and neck cancer; Post radiotherapy complications in patients with head and neck cancer; TENS machine in production of sa; Transcutaneous Electrical Nerve stimulation of the salivary glands; Xerostomia

Year:  2021        PMID: 33664943      PMCID: PMC7903056          DOI: 10.1016/j.amsu.2021.01.094

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  24 in total

Review 1.  Interventions for the management of dry mouth: topical therapies.

Authors:  Susan Furness; Helen V Worthington; Gemma Bryan; Sarah Birchenough; Roddy McMillan
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Interventions for the management of dry mouth: non-pharmacological interventions.

Authors:  Susan Furness; Gemma Bryan; Roddy McMillan; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2013-08-30

Review 3.  Neuroelectrostimulation in treatment of hyposalivation and xerostomia in Sjögren's syndrome: a salivary pacemaker.

Authors:  Stefano Fedele; Andy Wolff; Frank Strietzel; Rafael Martín-Granizo López; Stephen R Porter; Yrjö T Konttinen
Journal:  J Rheumatol       Date:  2008-08       Impact factor: 4.666

4.  Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study.

Authors:  Raimond K W Wong; Snehal Deshmukh; Gwen Wyatt; Stephen Sagar; Anurag K Singh; Khalil Sultanem; Phuc F Nguyen-Tân; Sue S Yom; Joseph Cardinale; Min Yao; Ian Hodson; Chance L Matthiesen; John Suh; Harish Thakrar; Stephanie L Pugh; Lawrence Berk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

5.  Prospective phase II study of the efficacy of transcutaneous electrical nerve stimulation in post-radiation patients.

Authors:  A Vijayan; M L Asha; S Babu; S Chakraborty
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-09-26       Impact factor: 4.126

Review 6.  Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis.

Authors:  Valeria Mercadante; Arwa Al Hamad; Giovanni Lodi; Stephen Porter; Stefano Fedele
Journal:  Oral Oncol       Date:  2017-01-19       Impact factor: 5.337

7.  A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy.

Authors:  Raimond K W Wong; Glenn W Jones; Stephen M Sagar; Angelica-Fargas Babjak; Tim Whelan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-10-01       Impact factor: 7.038

Review 8.  Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.

Authors:  Philip Riley; Anne-Marie Glenny; Fang Hua; Helen V Worthington
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

9.  Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines.

Authors:  H Mehanna; M Evans; M Beasley; S Chatterjee; M Dilkes; J Homer; J O'Hara; M Robinson; R Shaw; P Sloan
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

Review 10.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31
View more
  1 in total

Review 1.  Diagnosis, Prevention, and Treatment of Radiotherapy-Induced Xerostomia: A Review.

Authors:  Yanli Li; Xuehan Li; Runxuan Pang; Guang Yang; Mingxu Tian; Tengyu Zhao; Yunhan Sun; Eui-Seok Lee; Heng Bo Jiang; Jianmin Han
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.